Topics

GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer

14:33 EDT 9 Oct 2019 | Speciality Pharma Journal

LONDON, Oct. 9, 2019 /PRNewswire/ — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and as and when approval is received, all subsequent commercial …

Original Article: GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer"

Quick Search

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...